Clinical Trials

Carcinoma, Renal Cell

NCT02867592 2026-05-27

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

CNSEndocrineGastrointestinalGenitourinarySarcoma

109 enrolled 24 charts

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT03388619 2026-05-27

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Phase 1 Completed

30 enrolled 16 charts

Prostatic Neoplasms

NCT03595124 2026-05-27

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

15 enrolled 15 charts

Carcinoma, Renal Cell

NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

20 enrolled 9 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

47 enrolled 16 charts

Hormone Sensitive Prostate Cancer

NCT04284774 2026-05-27

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidMyeloidSarcoma

5 enrolled 9 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Wilms Tumor, Neuroblastoma, Pheochromocytoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Thyroid Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT04320888 2026-05-27

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

1 enrolled 3 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03570827 2026-05-26

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

53 enrolled 11 charts

Prostatic Neoplasms

NCT03934840 2026-05-26

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

61 enrolled 16 charts

Prostatic Neoplasms

NCT02316548 2026-05-22

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

14 enrolled 16 charts

Urinary Bladder Neoplasms

NCT03260894 2026-05-22

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Phase 3 Completed

129 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT01823562 2026-05-20

Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery

Phase 1 Completed

60 enrolled 12 charts

Prostatic Neoplasms

NCT01885949 2026-05-20

Tivozanib + Enzalutamide in Adv Prostate Cancer

5 enrolled 8 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03274687 2026-05-20

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Phase 3 Completed

296 enrolled 29 charts

Phase 1/2 Active not recruiting

Prostate Adenocarcinoma

NCT03317392 2026-05-20

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

132 enrolled 22 charts

Prostatic Neoplasms

NCT04037254 2026-05-20

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Phase 1/2 Completed

22 enrolled 13 charts

BreastCNSDermatologicGastrointestinalGenitourinaryThoracic

Prostatic Neoplasms

NCT04588246 2026-05-20

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Phase 3 Terminated

19 enrolled 19 charts

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Small Cell Lung Carcinoma

NCT00458536 2026-05-19

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

Phase 1/2 Completed

38 enrolled 4 charts

Kidney Neoplasms

NCT00183937 2026-05-15

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

15 enrolled 11 charts

Prostatic Neoplasms

NCT00544830 2026-05-15

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

29 enrolled 12 charts

PSA Level Greater Than Two

NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

39 enrolled 43 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT04019964 2026-05-15

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

8 enrolled 12 charts

Prostatic Neoplasms

NCT04716725 2026-05-15

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

15 enrolled 10 charts

Prostatic Neoplasms

NCT05730712 2026-05-15

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

7 enrolled 10 charts

Prostatic Neoplasms

NCT02312557 2026-05-14

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

58 enrolled 13 charts

Prostatic Neoplasms

NCT03644303 2026-05-14

TRAP

Phase NA Completed

86 enrolled 27 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT04030559 2026-05-14

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

11 enrolled 7 charts

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

755 enrolled 28 charts 1 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03047213 2026-05-13

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

17 enrolled 11 charts

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01624220 2026-05-12

A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

Phase NA Completed

41 enrolled 8 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Melanoma, Neoplasms, Unknown Primary, Prostatic Neoplasms, Sarcoma, Spinal Cord Neoplasms, Thyroid Neoplasms

NCT03047135 2026-05-12

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

51 enrolled 8 charts

Prostate

NCT03210714 2026-05-12

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)